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Purpose: To quantify the extent of cellular proliferation and immunohistochemically characterize the proliferating cell
types in epiretinal membranes (ERMs) from four different conditions: proliferative vitreoretinopathy (PVR), proliferative
diabetic retinopathy, post–retinal detachment, and idiopathic ERM.
Methods:  Forty-six  ERMs  were  removed  from  patients  undergoing  vitrectomy  and  immediately  fixed  in
paraformaldehyde. The membranes were processed whole and immunolabeled with either anti-MIB-1 or anti-SP6 to detect
the Ki-67 protein in proliferating cells, in combination with anti-glial fibrillary acidic protein or anti-vimentin to identify
glia, anti-ezrin to identify retinal pigment epithelial cells, Ricinus communis to identify immune cells, and Hoechst to
label nuclei. Digital images were collected using a laser scanning confocal microscope. The cell types were identified,
their combined proliferative indices were tabulated as the average number of anti-Ki-67-positive cells/mm2 of tissue, and
the number of dividing cells was related to the specific ocular condition and estimated disease duration.
Results: ERMs of all four types were shown to be highly cellular and contained proliferating cells identified as glia, retinal
pigment epithelium, and of immune origin. In general, membranes identified as PVR had many more Ki-67-positive cells
in comparison to those in the other three categories, with the average number of Ki-67-positive cells identified per mm2
of tissue being 20.9 for proliferative diabetic retinopathy, 138.3 for PVR, 12.2 for post–retinal detachment, and 19.3 for
idiopathic ERM. While all membrane types had dividing cells, their number was a relatively small fraction of the total
number of cells present.
Conclusions: The four ERM types studied demonstrated different cell types actively dividing at the time of removal,
confirming that proliferation is a common event and does continue over many months. The low number of dividing cells
at the time of removal in comparison to the total number of cells present, however, is an indicator that proliferation alone
may not be responsible for the problems observed with the ERMs. Treatment strategies may need to take into consideration
the timing of drug administration, as well as the contractile and possibly the inflammatory characteristics of the membranes
to prevent the ensuing effects on the retina.
Epiretinal membranes (ERMs) are sheets of cells and
extracellular matrix that occur on the vitreal surface of the
retina. The most common are idiopathic ERMs (iERMs) [1],
where  there  is  no  known  underlying  pathology;  however,
these can become clinically significant when they cause a
decrease  in  visual  acuity  or  metamorphopsia.  ERMs  also
occur as a result of disease or trauma of the eye, such as in
proliferative vitreoretinopathy (PVR), proliferative diabetic
retinopathy (PDR), and after successful retinal detachment
repair (ERMpRD). The latter occur in up to 6% of patients
and  behave  differently  from  PVR  membranes  [2].  The
different membrane types cause variable clinical symptoms,
such  as  metamorphopsia,  blurred  vision,  micropsia,  or
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macropsia,  and  problems  such  as  retinal  traction  or  even
traction  retinal  detachment.  In  all  cases,  however,  ERMs
appear to form initially as a result of cells from within the
retina, such as retinal pigment epithelium (RPE), Müller cells,
and astrocytes, that begin proliferating and migrating onto the
surface of the retina. The cells can either migrate through a
hole or tear in the retina, as is generally assumed to be the case
for RPE cells, or they can simply extend processes out of the
retina, as in the case of glial cells. Once this scaffold has
formed, other cell types present at the vitreoretinal interface,
such as hyalocytes and macrophages, may contribute to the
cells  undergoing  proliferation.  ERMs  become  a  serious
problem when they are contractile, often resulting in a folding
or  detachment  of  the  retina.  It  has  been  postulated  by
Machemer [3] and MacLeod and colleagues [4,5] that the
formation of ERMs is an aberrant form of healing response,
with an initial proliferation phase, after which the contraction
phase begins.
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1794Determining  the  exact  cell  types  present  in  the
membranes has been the focus of several previous studies
[4,6-12].  Using  light  or  electron  microscopy,  it  has  been
shown that many cells seem to change their morphological
characteristics as the ERM develops, making it difficult to
identify their origin [6-9]. In earlier studies [6,13,14], cells
were  identified  as  myofibroblasts,  hyalocytes,  fibrous
astrocytes, RPE, and macrophages using only morphology as
the  means  of  identification.  With  the  addition  of
immunocytochemistry, however, it has become apparent that
the most obvious cell types involved are glia, macrophages,
RPE cells, and fibroblasts [8,11,15,16]. Using antibodies to
the protein Ki-67 to label frozen and wax-embedded sections,
Heidenkummer  et  al.  [11,15]  quantified  levels  of  cell
proliferation in different types of ERMs. They suggested that
such data could help predict membrane behavior and thus be
of clinical significance when trying to predict the risk of
recurrence [11,15]. They developed a “proliferation index,”
which is the total number of cells divided by the number of
dividing cells. This index could help to clinically classify
membrane types and “quantitatively indicate the proliferation
potential of the ERM” [11,15]. However, the researchers did
not  correlate  the  proliferation  index  with  the  underlying
disease process in these studies, as they felt their numbers
were too low to separate the interindividual differences from
the disease process differences [11,15].
To understand the origins of dividing cell types in four
different  ERM  types  we  labeled  whole  membranes  with
antibodies to the Ki-67 protein to detect proliferating cells, and
antibodies specific to proteins for glial, immune, and RPE
cells. We then correlated the number of dividing cells and the
cell types to the type of ERM and the duration of the disease.
We show that proliferating glial, RPE, and immune cells could
be identified in all four types of ERMs, although the number
of dividing cells varied both with disease type and the duration
of  the  disease.  Implications  for  treatment  strategies  are
discussed.
METHODS
Forty-six ERMs from male and female patients undergoing
vitrectomy were obtained at the Academic Medical Center,
Amsterdam,  Netherlands.  The  ERMs  were  classified  as
follows: PDR (n=8), PVR (n=16), ERMpRD (n=5), and iERM
(n=17). Upon removal from the eye, the membranes were
immediately fixed in 4% paraformaldehyde in 0.1M sodium
cacodylate buffer, pH 7.4 (Electron Microscopy Sciences,
Fort Washington, PA) and stored at 4 °C until used. The period
between the diagnosis of the condition and the actual surgery
for the condition was between 1 and 25 months, i.e., some
patients presented and had surgery within one month, but
often ERMs were diagnosed clinically  that    did  not  require
immediate surgery, as the patient was asymptomatic. The
average duration (in months) that the membranes were present
in the eye before removal was 6.5 (range 2–14) for PDR, 1
(range 0.25–6) for PVR, 3 (range 1–5) for ERMpRD, and 11
(range 4–25) for iERM (Figure 1). The iERM group presented
the  longest  delay  between  diagnosis  and  removal  of  the
membrane, since the membranes often showed no effect on
vision at the time of diagnosis. It was more difficult to assess
the duration of the PDR membranes. In this case, we used
either  a  decrease  in  vision,  indicating  active
neovascularization  with  traction  or  bleeding,  or  the  first
evidence  of  fibrovascular  proliferation  noted  on  clinical
examination. All procedures had institutional research ethics
committee  approval  and  adhered  to  the  tenets  of  the
Declaration of Helsinki.
Immunocytochemistry: ERMs were processed whole in
1.5 ml Eppendorf tubes (Fisher Scientific, Pittsburgh, PA)
without  embedding  or  sectioning.  Following  fixation,  the
tissue samples were rinsed three times for 5 min each, and then
once for 1 h in phosphate buffer solution (PBS; 10× PBS
Figure 1. Graph illustrating the mean
length  of  time,  in  months,  between
diagnosis  and  epiretinal  membrane
removal for each disease condition. The
duration the membranes were present in
the eye ranged from 2 to 14 months for
proliferative  diabetic  retinopathy
(PDR),  0.25-  6  for  proliferative
vitreoretinopathy  (PVR),  1–5  for
epiretinal  membrane  post–retinal
detachment (ERMpRD), and 4–25 for
idiopathic ERM (iERM).
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1795stock:  250  ml  distilled  water,  21.92  g  NaCl,  0.67  g
NaH2PO4, 2.88 g Na2HPO4; stir well, dilute 1:10 in distilled
water, adjust pH to 7.4. Yields 0.086 M PBS). Since the
antibodies to Ki-67 (e.g., anti-MIB-1 and anti-SP6) require
antigen  retrieval  to  expose  the  epitopes,  the  tissue  was
incubated in citrate buffer (Dako, Carpinteria, CA) for 40 min
at 97 °C. Following cooling for 20 min at room temperature,
the tissue was rinsed three times in PBS (for 250 ml, add 21.92
g NaCl, 0.67 g NaH2PO4, and 2.88 g Na2HPO4) for 5 min each
time. The tissue was then incubated in 1:20 normal donkey
serum in a mixture that contained PBS, 0.5% BSA (BSA),
0.1% Triton X-100 (Fisher Scientific, Pittsburgh, PA), and
0.1%  azide  (PBTA)  overnight  at  4  °C  on  a  rotator.  The
following  day,  the  primary  antibodies  were  added  to  the
PBTA and the tissues were again left overnight at 4 °C on a
rotator. Next, either mouse monoclonal anti-MIB-1 (1:100;
Immunotech/Beckman  Coulter,  Fullerton,  CA)  or  rabbit
polyclonal  anti-SP6  (1:100;  Abcam,  Cambridge,  MA)
antibodies were used to label the Ki-67 protein (referred to
hereafter as Ki-67 labeling for simplification). Two different
markers were used to label Ki-67 because of the limitations in
triple  label  combinations.  Anti-MIB-1  was  used  in
combination  with  rabbit  polyclonal  antibodies  to  glial
fibrillary acidic protein (GFAP; 1:400; Dako, Carpinteria,
CA), which is an intermediate filament protein in glial cells,
as  well  as  biotinylated  Ricinus  communis  (ricin;  1:1000;
Vector Labs, Burlingame, CA), a lectin that labels immune
cells such as microglia and macrophages [17]. Anti-SP6 was
used  in  combination  with  antibodies  to  ezrin  (mouse
monoclonal; 1:10,000; Sigma, St. Louis, MO), a cytoskeletal
protein  in  the  microvilli  of  the  RPE,  and  either  vimentin
(chicken monoclonal; 1:2,000; Chemicon, Temecula, CA), an
intermediate filament protein present in glia, or biotinylated
Ricinus communis. After rinsing of the primary antibodies in
PBTA, the following secondary probes were added in PBTA,
and the mixture rotated overnight at 4 °C: donkey anti-mouse
conjugated to CY3 for MIB-1, donkey anti-rabbit conjugated
to CY2 for GFAP, streptavidin CY5 for ricin, donkey anti-
rabbit  conjugated  to  CY3  for  SP6,  donkey  anti-chicken
conjugated  to  CY2  for  vimentin,  and  donkey  anti-mouse
conjugated to CY2 for ezrin. All secondary antibodies were
purchased from Jackson ImmunoResearch (West Grove, PA)
and  used  at  a  concentration  of  1:200.  Streptavidin  was
purchased from Vector Labs (Burlingame, CA) and used at a
concentration of 1:100. On the final day, the sections were
rinsed  in  PBTA,  after  which  1:5,000  Hoechst  stain
(Invitrogen,  Carlsbad,  CA)  was  added  to  all  samples  for
identification of cell nuclei. The membranes were mounted on
glass slides in 5% n-propyl gallate in glycerol and viewed on
an  Olympus  FluoView  500  laser  scanning  confocal
microscope (New York, NY). Images were collected as a “z”
series  of  5  to  10  images  taken  at  0.5  µm  intervals.  For
quantitation, a single plane image was selected from the “z”
series that contained the greatest number of anti-Ki-67 labeled
nuclei.
Typically, 1 or 2 low magnification images (e.g., 200×)
were taken of each membrane depending on its size. The
number of anti-Ki-67-labeled cells, as well as the total number
of nuclei in the image plane were counted manually from the
digital images and normalized to the area of tissue for each
image, providing a population density (cells/mm2 hereafter
simply referred to as “density”) for total nuclei and the anti-
Ki-67 labeled cells (Table 1). Labeling with the proliferating
cell markers was correlated with the presence of glial, RPE,
and  immune  cell  markers,  while  images  were  viewed  in
Photoshop CS2 (Adobe, San Jose, CA), where magnification
and channel (color) intensity could be adjusted. This ensured
accuracy when determining which cell types were double
labeled with the Ki-67 markers.
Using antibodies to Ki-67 protein to identify proliferating
cells in histopathology specimens has several strengths: 1) the
antibodies will label dividing cells in all phases of the cell
cycle except G0 (resting) [18-20]; 2) they do not require living
tissue, as does commonly used 3H-thymidine labeling; and 3)
the antibodies allow relatively straightforward labeling with
multiple probes for the identification of different cell types.
RESULTS
Immunocytochemistry: Anti-Ki-67 (MIB-1, SP6) was used to
identify proliferating cells, anti-ezrin to identify RPE cells,
anti-GFAP or anti-vimentin to identify glial cells, ricin to
identify immune cells, and Hoechst staining used to identify
all nuclei (Figure 2 and Figure 3). However, since only four
fluorochromes  could  be  used  at  one  time,  and  not  all
antibodies could be used in combination because they were
made in the same species, the membranes were divided into
labeling groups: 1) anti-Ki-67+anti-GFAP+ricin+Hoechst, 2)
anti-Ki-67+anti-vimentin+anti-ezrin+  Hoechst,  or  3)  anti-
Ki-67+anti-ezrin+ricin+Hoechst. Each group contained some
anti-Ki-67-labeled  cells  not  labeled  with  any  cell-specific
marker. These are listed as “unidentified” in the tabulated data
(Table 1), and cells could fall into this category because they
were truly not recognized by any of the markers we used or
because their specific marker was not included in the marker
combination used to stain that specific membrane, i.e., RPE
cells in the first group, immune cells in the second group, or
glial cells in the third group.
All membranes were found to be multilayered and highly
cellular, as illustrated by the Hoechst nuclear stain (Figure 2,
Figure  3;  white  nuclei).  While  anti-Ki-67  labeled  nuclei
formed only a small part of this total population, they occurred
in all ERMs examined. In addition, all ERMs had cells labeled
with  the  markers  for  glial,  immune  (microglia  and
macrophages), and RPE cells; and examples from all of these
cell  types  were  anti-Ki-67  labeled  across  the  different
membranes. Indeed, most of the anti-Ki-67-labeled cells were
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(RPE) cells (C, D, E; green). Note that the amount of anti-glial fibrillary acidic protein (GFAP) labeled glia varied between membranes (A,
B, F). The anti-ezrin labeling appeared to encircle the cells, and the ricin labeling was prevalent in all samples. Scale bars equal 50 µm.
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1799also labeled with one of the cell-specific antibodies used here
(Table 1). Examples of typical staining patterns observed in
six different membranes from the PVR group are illustrated
in Figure 2. In general, most PVR membranes were richly
populated with glial and RPE cells, which usually appeared
clustered  in  separate  domains,  whereas  the  immune  cells
usually appeared dispersed throughout. In rare instances, the
PVR membranes had only a few widely dispersed cells stained
with a glial cell marker (Figure 2F) In addition, while anti-
GFAP staining appeared to fill the cytoplasm of the glial cells
(Figure 2A,B and Figure 3A-C), anti-ezrin staining appeared
to encircle the RPE cells, (Figure 2C-E). In situ, anti-ezrin
labels the apical microvilli of RPE cells; however, within the
ERMs, the RPE cells did not exhibit this type of polarity.
Examples of common staining patterns from pRD, iERM,
and PDR membranes labeled with anti-Ki-67 (MIB-1), anti-
GFAP,  and  ricin  are  shown  in  Figure  3A-C.  The  MIB-1
labeling alone is shown in the bottom half of each image to
allow better visualization of the dividing cells (arrows are
placed  for  reference  points).  All  three  samples  contained
dividing cells as well as glia and immune cells. Albeit at low
levels by comparison to PVR membranes, anti-ezrin labeling
of RPE cells was in fact also observed in pRD (in two out of
two membranes), PDR (in two out of two membranes), and
iERM membranes (in one out of seven membranes; Table 1).
Quantitation:  All  46  membranes  were  highly  cellular,  as
determined  by  Hoechst  staining  (Table  1;  “total  nuclei/
mm2”),  far  more  than  were  identified  by  the  anti-Ki-67
antibodies. All membranes from the four disease conditions
did, however, contain some dividing cells (Table 1).
The last column in Table 1 for total Ki-67+ cells/mm2 is
presented graphically as the average number of dividing cells
in Figure 4, which also shows the standard deviation for each
disease  group.  This  illustrates  that  PVR  membranes  were
clearly more active in terms of cell division than any of the
other  three  disease  conditions.  The  variability  (standard
deviation, Figure 4) is very large for each group but this is an
accurate  representation  of  the  great  variability  observed
between the different membranes.
The relative proportion of the different Ki-67 positive cell
types  (i.e.,  glia,  RPE,  immune,  and  unidentified)  in  the
different classes of ERMs is shown in Figure 5 and Figure 6.
(The brackets at the left of Table 1 show which membranes
were used to generate Figure 5 and Figure 6.) While useful for
illustrative purposes, the small number of samples in some
categories (Table 1) precluded the statistical analysis of this
data. Nevertheless, the graphs illustrate several interesting
Figure 3. Images of representative staining patterns on three different types of epiretinal membranes. The membranes were from post-retinal
detachment (pRD; A), of idiopathic origin (iERM; B), and proliferative diabetic retinopathy (PDR; C). Each membrane is labeled with anti-
MIB-1 (red), anti-glial fibrillary acidic protein (GFAP; green) and ricin (blue). In the lower half of each image the green and blue channels
are turned off to more easily see the anti-MIB-1 staining (arrows are for reference points). Scale bars equal 50 µm.
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1800trends in the data. First, while all membranes contained many
nuclei (gray bars, Figure 5 and Figure 6), only a small number
of these cells were Ki-67 labeled. Second, active glial cell
proliferation  was  observed  in  all  groups  except  for  the
ERMpRD  group,  although  antivimentin  or  anti-GFAP
labeling demonstrated the presence of glial cells suggesting
that much of glial proliferation occurred earlier in the course
of  membrane  formation.  Third,  Ki-67  labeled  cells  of
presumed immune origin (ricin-positive) were found in all
four disease groups, indicating an inflammatory component
to ERM formation regardless of the disease condition. Fourth,
Ki-67 labeled RPE cells were detected in the PDR and iERM
groups suggesting that even without a tear or break in the
retina, RPE cells can contribute to ERM formation.
An overall summary of the data are shown in Table 2
where the four disease conditions are compared in terms of 1)
disease duration, 2) average size of the ERM, 3) average
number of nuclei, and 4) average number of Ki-67 positive
cells.  From  this  table,  it  can  be  seen  that  while  PVR
membranes were in the eye for the shortest duration (1.5
months), they had the highest proliferation rates and greatest
density of nuclei. The iERM group had the longest duration,
with an average of 11.2 months from the start of clinical
symptoms, and had the largest average area, but were the most
sparsely populated with nuclei. Finally, although the duration
for ERMpRD, PDR and iERM ranged from 3 to 11 months,
the average number of Ki-67 cells was similar among them,
indicating  perhaps  that  a  relatively  constant  low  level  of
proliferation occurs throughout the time these membranes are
present in the eye.
DISCUSSION
Antibodies to the Ki-67 protein are routinely used to show
DNA  synthesis  and  presumed  cell  division  [18-20].  In
previous  studies  of  proliferation  in  ERMs  removed  from
human  patients,  these  antibodies  have  only  been  used  on
histological sections [11,15]. Our study, however, presents
unique data from studying proliferation in whole mounts of
ERMs by confocal imaging, thus providing a more complete
picture of the total number of nuclei and the number of cell
types undergoing proliferation at the time of removal from the
eye. Using anti-Ki-67 labeling in combination with cell-type
specific markers, we showed the presence of proliferating
glial, RPE, and immune cells in all four types of ERM studied
here, regardless of their duration in the eye. Although we
could not use all of the markers on each ERM, our general
impression is that most cells in the ERMs fell into one of these
three classes. Based on previous attempts to identify cells
within human ERMs, it is likely that fibroblasts, and immune
cells  not  labeled  by  the  lectin  ricin  make  up  a  minor
component  of  the  membranes  and  are  included  in  our
Figure 4. The average number of Ki-67
labeled cells/mm2 of membrane for the
four disease conditions plotted from the
total Ki-67/mm2 data in Table 1. PVR
membranes had the highest number of
dividing  cells  at  138.3/mm2,  with
proliferative diabetic retinopathy (PDR)
at  20.9,  epiretinal  membranes  post–
retinal detachment (ERMpRD) at 12.2,
and  idiopathic  ERM  (iERM)  at  19.3.
Error  bars  represent  the  standard
deviation.
Molecular Vision 2011; 17:1794-1805 <http://www.molvis.org/molvis/v17/a196> © 2011 Molecular Vision
1801“unidentified” category, although further study with specific
probes is required to confirm this conclusion.
While all membranes contained evidence for active cell
proliferation,  the  amount  varied  depending  upon  disease
condition. We observed that ERMs clinically assumed to be
rapidly growing (PVR), had both the greatest density of cells
and the greatest number of anti-Ki-67 labeled cells. These
results are in agreement with previous data reported from
histologically sectioned membranes [11,12,15,21,22]. Thus
proliferation is most likely a major contributor to the rapid
expansion of PVR membranes. In this study, the membranes
assumed to be “older” (e.g., iERMs) had a much lower level
of Ki-67 labeling, indicating that they may be less “reactive”
in terms of cellular proliferation. This is in contrast to results
reported  by  Zhang  et  al.  [12],  in  which  they  noted  no
difference in proliferation rates between membrane types.
There  are  two  possible  reasons  for  this  difference:  The
previous study included only two membranes classified as
“idiopathic,” and they used histological sections instead of
whole mounts. The low numbers of proliferating cells that
may be encountered in these membranes, along with the large
variability we observed, clearly demonstrates the need for
large sampling procedures in a study such as this.
The combined use of markers for all nuclei and those
specific to different cell types revealed several new findings.
We showed that these membranes are densely populated with
nuclei (ranging at the high end between more than 3,000 to
10,000  nuclei/mm2),  indicating  that  they  are  much  more
“cellular” than previously thought [8,11,15]. Indeed, this is
the  first  study  to  attempt  to  describe  the  overall  cellular
composition in individual ERMs using whole mounts instead
of histological sections, and the first to use Hoechst staining
as a means for estimating the number of nuclei present. Our
immunostaining data indicated that the greatest accumulation
of proliferating RPE cells occurred in PVR and ERMpRD,
with many fewer RPE cells in the PDR and iERM membranes.
We expected to find RPE cells in the PVR and ERMpRD
group, since the presence of retinal tears provides a passage
for these cells across the retina [6,14]. Interestingly, however,
the eyes with PDR and iERM membranes had no history of
retinal tears either before or during surgery, but did show
evidence of the presence of dividing RPE cells. These data
strongly support the possibility that RPE cells can migrate
through the intact retina [23,24]. We also found that while
glial cells were present in all membrane types, there was no
evidence  for  dividing  glia  in  the  ERMpRD  group.  This
suggests that a rapid phase of proliferation may have ended
early  after  detachment  and  what  we  observed  in  the
membranes preserved for this study are results of sampling
after  this  early  proliferative  phase,  the  expansion  of  cells
Figure  5.  Illustration  showing  the
average number of cells/mm2 for all four
types  of  epiretinal  membranes.  The
brackets  at  the  left  of  Table  1  show
which membranes were used to generate
this  figure.  For  each  membrane  type
(i.e.,  disease  condition)  the  average
number  of  cells/mm2  equals  the  total
number  of  nuclei/mm  (gray  bars)
divided  by  the  number  of  epiretinal
membranes (ERMs) in the group. The
average  number  of  glial  cells  (green
bars)  equals  the  number  of  glial
fibrillary acidic protein (GFAP) positive
cells that were also labeled with Ki-67/
mm2  in  each  ERM  divided  by  the
number of ERMs in the group. The value
for  immune  cells  (ricin  labeled  cells,
blue bars) was calculated the same way
while “unidentified” equals the value for
cells that were Ki-67 positive but not
labeled with any other markers (black
bars).  Proliferative  vitreoretinopathy
(PVR)  membranes  had  the  highest
number  of  dividing  cells.
Abbreviations:  proliferative  diabetic
retinopathy  (PDR);  proliferative
vitreoretinopathy  (PVR);  post–retinal
detachment  (ERMpRD);  idiopathic
ERM (iERM).
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1802residing in the membrane, and the growth of processes from
glial cells in which the cell body remains within the retina.
Indeed, following experimental retinal detachment in animal
models, most of the observed proliferation occurs in Müller
cells within the inner nuclear layer during the first three to four
days  after  detachment  [25,26].  As  detachment  (or
reattachment) time increases, these cells grow and expand
along  the  retinal  surface  [27].  In  later  stages  of  ERM
formation, it may be contraction rather than proliferation that
plays  the  key  role  in  causing  wrinkling  and  subsequent
redetachment  of  the  retina.  There  also  appears  to  be  a
significant cellular inflammatory component in all ERMs, as
shown by the ricin labeling. The presence of macrophages,
lymphocytes,  and  monocytes  in  ERMs  has  been  noted
previously; however, there has been no quantification of cells
involved  in  this  response  [28-32].  It  is  not  clear  whether
immune activation is in response to the initial (micro) trauma
of the disease or posterior vitreous detachment [33] or if it is
a self-perpetuating reaction, possibly caused by a breakdown
of the blood-retina barrier. However, the immune cells we
observed were not only found in all membranes, but were also
actively proliferating in all membrane types.
A parallel between wound healing and ERM formation
has  been  postulated  previously.  Our  data  are  generally
consistent  with  this  hypothesis.  ERM  formation  probably
involves  an  early  proliferative  phase  with  a  higher  cell
division rate and a slower cell division rate in the older, less
reactive membranes. After the proliferative phase, there is a
contractile  phase  with  the  deposition  and  contraction  of
extracellular  matrix  [2,3].  However,  it  was  somewhat
Figure  6.  Illustration  showing  the
average number of cells/mm2 for all four
types  of  epiretinal  membranes.  The
brackets  at  the  left  of  Table  1  show
which membranes were used to generate
this  figure.  For  each  membrane  type
(i.e.,  disease  condition),  the  average
number  of  cells/mm2  equals  the  total
number  of  nuclei  /mm  (gray  bars)
divided  by  the  number  of  epiretinal
membranes (ERMs) in the group. The
average  number  of  glial  cells  (green
bars) equals the number of vimentin-
positive cells that were also labeled with
Ki-67/mm2 in each ERM divided by the
number of ERMs in the group. The value
for  retinal  pigment  epithelium  (RPE)
cells (ezrin labeled cells, red bars) was
calculated  the  same  way,  while
“unidentified” equals the value for cells
that were Ki-67 positive but not labeled
with  any  other  markers  (black  bars).
Abbreviations:  proliferative  diabetic
retinopathy  (PDR);  proliferative
vitreoretinopathy  (PVR);  post–retinal
detachment  (ERMpRD);  idiopathic
ERM (iERM).
TABLE 2. TABLE SHOWING A SUMMARY OF THE DATA COLLECTED FROM THE 4 DISEASE CONDITIONS.
Parameters PDR PVR ERM pRD iERM
Avg disease duration, months 6.4 1.5 3 11.2
Avg area of ERM (mm2) 0.49 0.39 0.35 0.54
Avg No. nuclei / mm2 2925 4682 3577 2349
Avg No. Ki-67 cells / mm2 20.9 138.3 12.2 19.3
        The average duration the membranes were in the eye before removal is related to the average area of the membrane, number of
        total nuclei and number of total Ki-67 positive cells. Note that proliferative vitreoretinopathy (PVR) membranes were present
        in the eye for the shortest duration but had the most nuclei and divding cells whereas idiopathic epiretinal membrane (iERMs),
        which were present in the eye for the longest duration had fewer nuclei and divding cells compared to PVR.
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1803surprising  that  ERMs  during  what  would  be  clinically
described  as  the  active  phase  of  PVR  showed  less  cell
proliferation  than  might  be  expected.  This  suggests  that
perhaps much of the cellular proliferation is a very early event
in membrane formation and indeed may even occur within the
retina before the actual formation of clinically observable
membranes.  By  the  time  these  membranes  are  surgically
removed,  they  have  entered  the  secondary  phase  of
extracellular matrix deposition and contraction. This would
imply  that  clinical  treatments  aimed  against  membrane
formation would need to be given as early as possible. Once
the membrane has formed, anticontractile agents may be more
effective than antiproliferative drugs.
In conclusion, by using whole mounts of ERMs from
different disease conditions combined with nuclear staining
we have shown that the cellularity of ERMs is higher than
previously  shown  in  studies  that  relied  on  histological
sections.  The  whole  mounts  clearly  show  that  ERMs  are
composed of areas rich in cells alongside areas that are mostly
composed of extracellular matrix. By combining anti-Ki-67
antibodies  with  cell-specific  markers  we  have  identified
various cell types proliferating in the different types of ERM,
and find that the proportions differ among diseases. We also
showed that the proliferation rate is higher in membranes of
shorter duration, that is, those removed from the eye early
because it is assumed that the ERM is highly reactive. While
this may not be surprising, we have added new information
by providing estimates of the number of dividing cells for each
disease condition. Finally we show that in conditions where
there is no tear or hole in the retina, RPE cells can be observed
in the ERMs. The fact that the overall numbers of dividing
cells were relatively low compared to the total number of
nuclei  in  the  membranes  suggests  that  much  of  the
proliferation  may  occur  early,  before  the  actual  clinical
manifestations,  which  ultimately  may  have  significant
implications  for  timing  of  therapeutic  and  clinical
interventions.
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